Other equities analysts have also issued research reports about the company. Svb Leerink initiated coverage on Aptinyx in a research note on Thursday, June 20th. They issued an “outperform” rating and a $12.00 price target on the stock. Cantor Fitzgerald reiterated a “buy” rating on shares of Aptinyx in a research note on Tuesday, April 30th. Zacks Investment Research upgraded Aptinyx from a “hold” rating to a “buy” rating and set a $4.25 price target on the stock in a research note on Tuesday, July 16th. Finally, Cowen reiterated a “buy” rating on shares of Aptinyx in a research note on Monday, June 10th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $12.71.
NASDAQ APTX traded down $0.23 during midday trading on Thursday, hitting $3.40. The company had a trading volume of 147,612 shares, compared to its average volume of 168,232. The stock has a market cap of $124.85 million, a P/E ratio of -1.29 and a beta of -0.04. The business has a 50-day moving average of $3.55. Aptinyx has a twelve month low of $2.88 and a twelve month high of $32.25.
In other Aptinyx news, Director Henry O. Gosebruch purchased 100,000 shares of the firm’s stock in a transaction dated Wednesday, May 8th. The shares were bought at an average price of $3.86 per share, for a total transaction of $386,000.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 8.47% of the company’s stock.
Institutional investors and hedge funds have recently modified their holdings of the company. Great West Life Assurance Co. Can bought a new position in shares of Aptinyx in the 4th quarter valued at $40,000. Gabelli Funds LLC bought a new stake in Aptinyx during the 1st quarter worth $44,000. SG Americas Securities LLC bought a new stake in Aptinyx during the 2nd quarter worth $49,000. Alambic Investment Management L.P. bought a new stake in Aptinyx during the 1st quarter worth $87,000. Finally, Metropolitan Life Insurance Co. NY grew its position in Aptinyx by 356.6% during the 4th quarter. Metropolitan Life Insurance Co. NY now owns 7,237 shares of the company’s stock worth $120,000 after acquiring an additional 5,652 shares during the last quarter. Institutional investors own 58.37% of the company’s stock.
Aptinyx Company Profile
Aptinyx Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. It is developing NYX-2925 that is in Phase II clinical trial for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II exploratory clinical trial for fibromyalgia; and NYX-783, an NMDAr receptor that is in Phase I clinical trial for the treatment of post-traumatic stress disorder.
Recommended Story: What is a Roth IRA?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Aptinyx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptinyx and related companies with MarketBeat.com's FREE daily email newsletter.